89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

April 17, 2024

https://www.globenewswire.com/news-release/2024/04/17/2864947/0/en/89bio-Appoints-Biotech-Industry-Veteran-Martin-Babler-to-its-Board-of-Directors.html

SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Martin Babler to its Board of Directors, effective April 13, 2024. Mr. Babler, a highly successful executive who brings valuable industry experience to 89bio, currently serves as President, Chief Executive Officer and Chairman of the Board of Alumis Therapeutics.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.